stockportfolio.pro
Jazz Pharmaceuticals plc (JAZZ)
Healthcare · Biotechnology · NasdaqGS
Jazz Pharmaceuticals plc revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.49B | $1.62B | $1.89B | $2.16B | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $396.83M | $487.85M | $447.10M | $523.37M | $238.62M | $-329.67M | $-224.06M | $414.83M | $560.12M | $-356.15M |
| Net margin | 26.7% | 30.1% | 23.6% | 24.2% | 10.1% | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
Source: Jazz Pharmaceuticals plc SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Jazz Pharmaceuticals plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track JAZZ in your portfolio →
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Jazz Pharmaceuticals plc — frequently asked questions
What is Jazz Pharmaceuticals plc's revenue?
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $4.27B for fiscal year 2025, up 4.9% from the prior year, according to its SEC filings.
Is Jazz Pharmaceuticals plc profitable?
No — JAZZ reported a net loss of $-356.15M in fiscal 2025.
What is JAZZ's P/E ratio?
Jazz Pharmaceuticals plc trades at a price-to-earnings ratio of about 2080.5 based on the latest data in our nightly-refreshed cache.
How fast is Jazz Pharmaceuticals plc growing?
JAZZ's revenue grew at roughly 12.5% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Jazz Pharmaceuticals plc's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.